Ireland
--:--IST
Recruiting Phase 4

Short-term Intravenous Fluids for Prevention of Post-ERCP Pancreatitis

NCT06260878 · tracked via the Priya Life Science Canada tracker
Phase
Phase 4
Started
2024-11-22
Last updated
2026-04-29

Condition(s) studied

Post-ERCP Acute Pancreatitis

Investigational drug(s) / intervention(s)

Intravenous Ringer's lactate

Intravenous Ringer's lactate: Intravenous Ringer's lactate

Study summary

This study will explore the efficacies of several practical short-term (peri-procedural) intravenous fluid regimens in the prevention of post- endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). PEP is the most common serious ERCP-related adverse event (AE), occurring in 5-15% of patients, and associated with significant morbidity, mortality, and healthcare utilization. Given the current lack of data on effectiveness of short-term fluid regimens in PEP prevention to inform practice, the results of the proposed study have the strong potential to impact ERCP practices worldwide, whether positive or negative.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. age 18-75 years (due to higher likelihood of undiagnosed cardiac disease or renal insufficiency in patients \>75 years of age) 2. ability to give informed consent 3. native major papillary anatomy 4. ability and willingness to obtain bloodwork the day after ERCP Exclusion Criteria: 1. prior ERCP with sphincterotomy and/or sphincteroplasty 2. confirmed or suspected cholangitis or sepsis 3. confirmed pancreatitis, hyperlipasemia, or hyperamylasemia within the preceding 7 days 4. NYHA Class II or greater heart failure 5. active pulmonary edema 6. myocardial infarction or ischemia within the preceding 3 months 7. renal insufficiency with CrCl \< 40 mL/minute 8. CPT Class B or C cirrhosis and/or end-stage liver disease 9. room air oxygen saturation \<90% or requirement of home O2 10. hypernatremia with Na+ ≥ 150 mEq/L or Na+ \<130 mEq/L 11. uncontrolled hypertension or hypotension 12. pregnant status

Primary outcome measure(s)

  • Serum amylase — 24 hours

Trial sites (1)

FacilityCityRegionStatus
Peter Lougheed Centre Calgary Alberta Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06260878 on ClinicalTrials.gov ↗ ← All trials in Canada